Expiration date: 04/2025

Composition:

Triazavirin capsules, solid gelatin capsules of size 1, yellow body and red lid. The contents of the capsules are fine crystalline powder or granules of yellow or yellow-green color.

1 caps.:

- methylthionitrooxodigydrotriazolotriazinide sodium dihydrate (triazavirin) 250 mg

Excipients: Calcium stearate 2 mg.

The weight of the capsule contents is 252 mg.

The composition of the shell capsules:

Capsule (case) no. 1: titanium dioxide (E171), yellow quinoline (E104), yellow "sunset" (E110), medical gelatin.

Capsule (cap) no. 1: titanium dioxide (E171), azorubin (E122), medical gelatin.

Weight of the capsule with a content of 328 mg.

Pharmaceutical group: Antiviral agent.

Pharmacology: the Active substance of the drug Triazavirin® is a synthetic analog of the bases of purine nucleosides (guanine) with a pronounced antiviral effect. It has a wide range of antiviral activity against RNA-containing viruses.

The main mechanism of action of Triazavirin® is inhibition of viral RNA synthesis and replication of genomic fragments.

Pharmacokinetics: after ingestion, it is rapidly absorbed in the gastrointestinal tract. The maximum concentration (Cmax) is reached in an average of 1-1. 5 hours. Cmax with the recommended dosing mode is an average of 4, 8 micrograms / ml. the AUC Value (the area under the pharmacokinetic curve "concentration-time") of blood is 12, 8 micrograms/h * ml. the half-life (T1 / 2) is 1-1. 5 hours. the Kidneys output unchanged from 15 to 45% of the drug. The average value of the calculated clearance is 246 ml/min.

Indications: treatment of influenza in adults. If necessary, combine with the use of symptomatic drugs.

Category of action on the fetus: the use of Triazavirin during pregnancy has not been studied.

The use of the drug during lactation has not been studied, so if you need to use the drug during lactation, you should stop breastfeeding.

Contraindications:

• hypersensitivity to the components of the drug Triazavirin,
• pregnancy,
• breastfeeding period,
• children under 18 years of age (efficacy and safety not defined),
• renal / hepatic insufficiency (efficacy and safety not determined).

Dosage: Triazavirin® is administered orally regardless of food intake.

Therapeutic dose:

The drug should be started no later than 2 days after the onset of the disease (the appearance of clinical symptoms) 1 capsule (250 mg) 3 times a day (daily dose-750 mg) for 5 days.

If necessary, the treatment can be continued for up to 7 days.

Side effects:

• allergic reactions,
• from the digestive system: dyspeptic disorders (flatulence, diarrhea, nausea, vomiting).

If any of the side effects listed in the instructions are getting worse, or you notice any other side effects not listed in the instructions, let your doctor know.

Overdose: Symptoms: nausea, vomiting, dyspeptic disorders, stomach pain.

Treatment: symptomatic therapy. If you have any of these symptoms you must stop taking the drug.

Interaction: Interaction with analogues of purine and pyrimidine bases during antitumor therapy may lead to increased toxicity of the drug.

Simultaneous use of Triazavirin with ribavirin requires a reduction in the dose of ribavirin.

Special instructions: the Effect on the ability to drive vehicles and mechanisms has not been studied.